Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report published on Saturday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS stock opened at $0.02 on Friday. Ayala Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $1.49. The stock has a market cap of $852,600.00, a PE ratio of 0.00 and a beta of 1.51. The business has a 50-day simple moving average of $0.07 and a 200-day simple moving average of $0.34.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.